Resmed Fair Value
RM
The fair market value of RME.SW stock is 267.57 CHF. Relative to the market price of 0 CHF Resmed is undervalued by 24.8%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Resmed Valuation
The fair value level of 267.57 CHF can be considered as an effective entry point for long-term investors to start investing in RME.SW stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Market price:
RME.SW stock is undervalued
It means the current price may concern as a Moderate Risk Entry Point
Resmed Inc Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
67.24
2
Median P/E over 5 years
40
3
Minimum P/E over 5 years
29.41
4
Earning per share (last 12 months)
7.57 USD
Maximum value
1
x
4
=
449.72 CHF
Fair value
2
x
4
=
267.57 CHF
Minimum value
3
x
4
=
196.69 CHF
Resmed Inc price metrics
11.91
Annual return (geometric mean)
36.14
Risk (standard deviation) of returns
β
0.82
Beta (volatility compared to market)